Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT05779995

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

Randomized, Double-blind, Placebo-controlled Phase Ib/Ⅱa Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of XW001 Inhalation in Children With Respiratory Syncytial Virus (RSV) Infection in China

Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.

Conditions RSV Infection

Interventions Placebo XW001

Updated 6 times since 2023 Last updated: Aug 13, 2025 Started: Apr 20, 2023 Primary completion: Oct 10, 2023 Completion: Jan 8, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates RSV Infection and is currently completed. Hangzhou Sciwind Biosciences Co., Ltd. leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2

Status: Unknown → Completed
Aug 2025 — Sep 2025 [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Aug 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Apr 2023 — Aug 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hangzhou Sciwind Biosciences Co., Ltd.

Data source: Hangzhou Sciwind Biosciences Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China